通过整合血遗传学和蛋白质组来确定多发性硬化症的新型药物标

Yi Liu1, Qian Wang2, Yuhui Zhao2

  • 1Department of Neurology, First Affiliated Hospital of Guangxi Medical University, Nanning, China; Department of Neurology, Shanxi Provincial People's Hospital, The Fifth Clinical Medical College of Shanxi Medical University, Taiyuan, China.

PubMed
概括

这项研究确定了与多发性硬化症 (MS) 风险相关的CR1和CD59等关键蛋白质. 这些发现突出了开发新型多发性硬化疗法的潜在新药标.